About: Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.10 (+1.85%)
TVRD NASDAQ Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc. share price
TVRD price activity
Last Price
$1.100
Change (24hr)
0.02 USD (1.85%)
Volume
136.34K
Volume (4w avg)
-
Open
$1.08
Day Range
$1.04 - $1.11
Previous Close
$1.08
Last Trade
07 Oct, 8:00 pm GMT+0
Delayed
07 Oct, 8:00 pm GMT+0
TVRD price performance
Delayed
07 Oct, 8:00 pm GMT+0
TVRD Market Signals